Market Forecasts and Industry Analysis Global Dalteparin Sodium Market Outlook 2016-2021

Dalteparin Sodium Market Size & Growth
Report 2017: Radiant Insights, Inc
“This report provides detailed analysis of worldwide
markets for Dalteparin Sodium from 2011-2015 and
provides extensive market forecasts 2016-2021 by
region/country and subsectors.”
Dalteparin is a low molecular weight heparin. It is marketed as Fragmin by Pfizer Inc. Like
other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein
thrombosis and pulmonary embolism. It is normally administered by self-injection.
The CLOT study, published in 2003, showed that in patients with malignancy and acute venous
thromboembolism, dalteparin was more effective than warfarin in reducing the risk of recurrent
embolic events. Dalteparin is not superior to unfractionated heparin in preventing blood clots.
Heparins are cleared by the kidneys, but studies have shown that dalteparin does not accumulate
even if kidney function is reduced.
Complete Report Available @ https://www.radiantinsights.com/research/global-
dalteparin-sodium-market-outlook-2016-2021
Follow Us: